Talipexole dihydrochloride (also known as B-HT920, Domnin, B-HT-920 dihydrochloride) is a novel and potent dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays anti-parkinsonian activity. Talipexole is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist. The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints. In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.
理化性质和储存条件
| Name: Talipexole HCl CAS#: 36085-73-1 Chemical Formula: C10H17Cl2N3S Exact Mass: Molecular Weight: 282.227 Elemental Analysis: C, 42.56; H, 6.07; Cl, 25.12; N, 14.89; S, 11.36
|
---|
Storage | -20℃ for 3 years in powder form |
---|
-80℃ for 2 years in solvent |
Technical Information | Synonym: B-HT 920, B-HT-920, B-HT920, Talipexole HCl, Talipexole dihydrochloride, Domnin IUPAC/Chemical Name: 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo(4,5-d)azepine dihydrochloride InChi Key: DPQAXNSOFFYKDS-UHFFFAOYSA-N InChi Code: InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H SMILES Code: NC(S1)=NC2=C1CCN(CC=C)CC2.[H]Cl.[H]Cl |
---|